Isomorphic Labs, a spin-off from Google's DeepMind, has secured $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet. The London-based company, under the leadership of Nobel laureate Sir Demis Hassabis, aims to leverage artificial intelligence to revolutionise drug design and development. The substantial investment will support the enhancement of their AI drug design engine and progression of their programmes into clinical stages. Collaborations with pharmaceutical leaders like Novartis and Eli Lilly are already underway, utilising tools such as DeepMind's AlphaFold and proprietary AI models. Despite reporting significant losses and increased R&D expenses, Isomorphic Labs remains optimistic about its expansion and contributions to AI-driven healthcare advancements.
